Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07393204Active Not Recruiting

Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL

Role: lead

NCT07278921Recruiting

Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).

Role: lead

NCT07181785Completed

Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.

Role: lead

NCT00801216Phase 2Completed

High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement

Role: lead

All 4 trials loaded